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Abstract
Background: Intensive care unit (ICU)-acquired weakness is the most important cause of failed functional outcome
in survivors of critical care. Most damage occurs during the first week when patients are not cooperative enough
with conventional rehabilitation. Functional electrical stimulation-assisted cycle ergometry (FES-CE) applied within
48 h of ICU admission may improve muscle function and long-term outcome.
Methods: An assessor-blinded, pragmatic, single-centre randomized controlled trial will be performed. Adults (n = 150)
mechanically ventilated for < 48 h from four ICUs who are estimated to need > 7 days of critical care will be randomized
(1:1) to receive either standard of care or FES-CE-based intensified rehabilitation, which will continue until ICU discharge.
Primary outcome: quality of life measured by 36-Item Short Form Health Survey score at 6months. Secondary outcomes:
functional performance at ICU discharge, muscle mass (vastus ultrasound, N-balance) and function (Medical Research
Council score, insulin sensitivity). In a subgroup (n = 30) we will assess insulin sensitivity and perform skeletal muscle
biopsies to look at mitochondrial function, fibre typing and regulatory protein expression.
Trial registration: ClinicalTrials.gov, NCT02864745. Registered on 12 August 2016.
Keywords: Early rehabilitation, Critically ill, Intensive care unit, Functional electrical stimulation-assisted cycle ergometry,
Mobility, Physical therapy
Background
Functional disability, a natural consequence of weakness,
is a frequent and long-lasting complication in survivors
of critical illness [1–3]. Over recent decades, mortality
from acute critical illness has decreased with a consequent
increasing number of ICU survivors. Understanding the
post-ICU morbidity experienced by these survivors has
become increasingly important. The greatest burdens that
survivors of critical illness face are related to neuromuscu-
lar dysfunction and neuropsychological maladjustment
[4]. In particular, neuromuscular abnormalities during
critical illness are common, with a median prevalence of
57% [1]. In both patients with chronic critical illness and
survivors of severe critical illness, neuromuscular weak-
ness may be substantial and persistent [5], resulting in im-
portant decrements in physical function and quality of life
for years after discharge [1, 2].
In the past, routine features of general care provided
in the ICU included liberal use of sedation and
immobilization of the patient, which were thought to be
necessary for facilitating interventions to normalize
physiological function by artificial means. Over the last
decade, there has been a paradigm shift away from this
approach towards a more conservative treatment phil-
osophy for patients in the ICU [4, 6, 7]. This paradigm
shift is consistent with the observation that long-term
physical problems in survivors of critical illness, particu-
larly those with respiratory failure, may result from the
protracted ICU stay and period of immobilization during
which the patient is receiving organ support that is
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essential for survival [2, 4]. In line with this, a daily
interruption of sedation policy has been widely adopted
and proven to be beneficial [8] and early mobilization
culture is spreading quickly across ICUs [9–13]. Indeed,
these strategies, together with early physical therapy [9,
11, 12, 14–20], are the only safe [12, 20–22] and effect-
ive interventions in the prevention of long-term neuro-
muscular disability in survivors of intensive care. It
should be stressed that in these studies early rehabilita-
tion is defined as starting between days 2 and 5 of the
ICU stay [9, 11, 12, 14–19] or as an activity beginning
before ICU discharge [20].
Standard “early” rehabilitation cannot be started early
enough, and FES-CE may be a solution to this dilemma.
The first week in the ICU is critical as muscle mass and
function is lost quickly. Immobility-associated muscle
loss is evident as early as within 18–48 h of onset of
acute critical illness or severe injury [23, 24] and is
greatest during the first 2–3 weeks of critical illness [25,
26]. Up to 40% loss of muscle strength can occur within
the first week of immobilization, with a daily rate of
strength loss between 1.0 and 5.5% [27]. A 10–14% de-
crease in cross-sectional measurements of the rectus
femoris muscle has been observed within the first week
of the ICU stay [26]. Conventional rehabilitation during
the first few days in the ICU is indeed limited in patients
who are sedated and mechanically ventilated, and typic-
ally consists of passive limb movements, with or without
the use of stretch reflex [16, 20]. Schweickert et al. [16]
provided the earliest (within 48 h of intubation) and lar-
gest (26 ± 14min a day for patients on mechanical venti-
lation) dose of rehabilitation and reported improvements
of physical function at hospital discharge, but no mea-
surements beyond. Active rehabilitation is delayed until
the neurological condition of the patient improves
enough to facilitate participation. In the sickest patients,
who are at particular risk of developing ICU-acquired
weakness (ICUAW), sedation and immobility may be
prolonged well beyond the first week, when established
damage to the muscle has already occurred.
There are several ways to deliver more effective phys-
ical exercise therapy to patients who are sedated and
mechanically ventilated. For example, physical exercise
can be delivered effectively and safely by passive supine
cycling on a bicycle ergometer [15, 18, 28–30]. More re-
cently, electrical neuromuscular stimulation (NMES) has
been developed to mimic active exercise in patients who
lack voluntary muscle activity [31–39]. During NMES,
cutaneous electrodes placed over specific muscle groups
electrically trigger muscle contractions. In order to
achieve maximum efficacy, passive cycling and NMES
can be delivered simultaneously and synchronized to
produce a coordinated pattern of movements. The tech-
nique is called FES-CE (functional electrical stimulation-
assisted cycle ergometry). There is a large body of ex-
perience with these methods in the rehabilitation of pa-
tients with stroke and spinal cord injuries (reviewed in
[40]). The method is effective in preventing the loss of
muscle mass [41] and has been shown to improve ana-
bolic resistance and insulin sensitivity in quadriplegic
patients [42, 43].
The only study of FES-CE in critical illness is the pilot
trial by Parry et al. [44], where the feasibility and safety
of FES-CE was demonstrated in a small cohort of
critically ill patients (eight patients received the FES-CE
intervention, versus eight controls). Patients in the inter-
vention group showed significant improvements in the
Physical Function in Intensive Care Test and a faster re-
covery of functional milestones (e.g. time to stand from
lying, walking on the spot). However, the mechanism by
which this occurred is unknown. There are no data on
the effect of FES-CE on long-term functional outcome
in ICU survivors. In healthy volunteers [45] and patients
with spinal cord injury [46], unloaded FES-CE can in-
crease whole-body oxygen consumption. It is unknown
whether these effects, including improving insulin sensi-
tivity and protein metabolism [47], can also be achieved
in critically ill patients.
Rationale
Mechanisms of muscle wasting and ICUAW
Pathophysiology of ICUAW is complex and multifactor-
ial (reviewed in [4]), and there is a growing body of evi-
dence suggesting the role of sarcopenia and metabolic
derangement of skeletal muscle.
Firstly, insulin resistance is a well-known comorbidity
in critical illness [48], contributing to and aggravating
complications such as severe infections, organ dysfunc-
tion and death, and has also been implicated in the ICU-
acquired weakness. Two main consequences of insulin
resistance are hyperglycaemia and “anabolic resistance”.
It has been observed that the provision of protein and
energy to support the enhanced hypermetabolic de-
mands of ICU patients is unable to prevent the rapid
loss of muscle mass [49]. Indeed, skeletal muscle insulin
resistance is the likely reason why nutritional support
further exacerbates hyperglycaemia. Insulin therapy is
often used in ICU patients to try and combat this, but it
appears to be ineffective in ICU-acquired weakness and
its safety in the ICU setting has been questioned [50].
Physical activity is an attractive alternative intervention
target as it has profound effects on substrate metabolism
in contracting skeletal muscle, with a single bout of
muscle contraction known to increase muscle glucose
uptake several fold and sensitize the muscle to insulin
and the anabolic effects of amino acids for up to 24 h,
including in individuals where insulin and anabolic re-
sistance is evident [51]. It is not known whether
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intensified rehabilitation can improve the insulin effect
on glucose uptake and whether it influences the stimula-
tory effect of insulin and amino acids on muscle protein
synthesis.
Secondly, mitochondrial dysfunction in skeletal muscle
may play a role in the development of ICUAW. Mito-
chondrial depletion and dysfunction of mitochondrial re-
spiratory complexes I and IV has been demonstrated in
acute severe sepsis in association with multiorgan failure
and death [52], and early activation of mitochondrial
biogenesis predicted survival [53]. Our group has re-
cently demonstrated in two pilot studies [54, 55] that,
compared to healthy controls, there is a 50% reduction
of mitochondrial functional capacity in skeletal muscle
in the patients with protracted critical illness and
ICUAW. This is accompanied by a significant relative
increase in the abundance and functional capacity of re-
spiratory complex II, which delivers electrons to the re-
spiratory chain from fatty acid oxidation [54]. Weber-
Carstens et al. [48] demonstrated that insulin fails to ac-
tivate GLUT-4 translocation to cellular membranes in
patients with ICUAW, causing skeletal muscle “intracel-
lular glucose starvation” and a failure of AMP-activated
protein kinase to respond to the impairment of ATP
production. Most notably, in five subjects, these abnor-
malities were alleviated by NMES. In light of this, the
relative increase of complex II capacity observed in our
pilot study may represent a functional adaptation of
muscle to the increased reliance on fatty acid oxidation.
It is not known whether the severity of mitochondrial
functional alteration reflects the degree of insulin resist-
ance and the severity of muscle weakness, and whether
the delivery of very early FES-CE has a potential to influ-
ence these changes.
In the light of this, we hypothesize the following:
H1: As most of the damage to the structure and
function of skeletal muscle occurs during the first
week, intensified goal-directed rehabilitation, which in-
cludes FES-CE and starts within 48 h after ICU admis-
sion, improves the functional outcome of ICU survivors
at 6 months when compared to the standard of care.
H2: The intervention, as compared to standard of care,
shall preserve muscle mass and improve muscle power
at ICU discharge.
H3: The intervention, as compared to standard of care,
shall increase insulin-mediated whole-body oxidative
glucose disposal and mitochondrial functional indices.
Objectives
1. To investigate, in a pragmatic, prospective,
randomized, controlled, assessor-blinded trial, the
effects of very early intensive rehabilitation using a
goal-directed protocol that includes FES-CE in
mechanically ventilated ICU patients predicted to
need a protracted ICU stay
2. To perform more detailed metabolic studies,
including serial muscle biopsies and using
euglycaemic hyperinsulinaemic clamps, in a nested
subgroup. Insulin sensitivity in the whole study
population will be compared by glucose control and
consumption of intravenous insulin required to
control blood glucose
Primary outcome
The primary outcome is the physical component of the
SF-36 quality of life questionnaire measured in ICU sur-
vivors at 6 months. Based on the study by Kayambu
et al. [12], where this measure was 60 ± 29 points in the
control group, our study is powered to detect a change
by 15 points or more, which is within the limits deter-
mined as clinically important for patients with COPD,
asthma and myocardial infarction [56]. The SF-36 has
been validated in the Czech Republic and endorsed by
the Institution for Health Information and Statistics
(https://www.uzis.cz/en/node/8159).
Secondary outcomes
 Four-item Physical Fitness in Intensive Care Test
(time frame: at 28 days or discharge from the ICU,
whichever occurs earlier) as the functional outcome
at ICU D/C
 Muscle mass measured by rectus muscle cross-
sectional area on B-mode ultrasound (time frame: at
7-day intervals up to day 28 or discharge from the
ICU, whichever occurs earlier)
 Nitrogen balance measured in grams per metre-
squared of body surface area (time frame: at 7-day
intervals up to day 28 day or discharge from the
ICU, whichever occurs earlier) and the cumulative
the difference between nitrogen intake and output
 Muscle power as per the Medical Research Council
(MRC) score (time frame: at 7-day intervals up to
day 28 or discharge from the ICU, whichever occurs
earlier)
 Number of ventilator-free days (time frame: at 28
days); that is, number of days, out of 28 days after
admission, that the patient has NOT been supported
by mechanical ventilation
 Number of rehabilitation interruptions due to
physiological deterioration (time frame: at 28 days or
discharge from the ICU, whichever occurs earlier)
 Number of episodes of elevated intracranial pressure
(time frame: at 28 days or discharge from the ICU,
whichever occurs earlier)
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 Number of dialysis interruptions (time frame: at 28
days or discharge from the ICU, whichever occurs
earlier)
 Length of ICU stay in days (time frame: at 6
months)
Study population
One hundred and fifty participants meeting the eligibility
criteria will be recruited in four ICUs at FNKV Univer-
sity Hospital.
Inclusion criteria: age ≥ 18 years; mechanical ventila-
tion, or imminent need of it at presentation; predicted
ICU length of stay ≥ 7 days.
Exclusion criteria: known primary systemic neuromus-
cular disease or spinal cord lesion at admission; severe
lower limb injury or amputation; bedridden premorbid
state (Charleston Comorbidity Score > 4); approaching
imminent death or withdrawal of medical treatment
within 24 h; pregnancy; presence of external fixator or
superficial metallic implants in lower limbs; open
wounds or skin abrasions at electrode application points;
presence of pacemaker, implanted defibrillator, or other
implanted electronic medical device; predicted as unable
to receive first rehabilitation session within 72 h of ad-
mission or transferred from another ICU after more
than 24 h of mechanical ventilation; presence of other
condition preventing the use of FES-CE or considered
unsuitable for the study by a responsible medical team;
prior participation in another functional outcome-based
intervention research study.
With the exception that we do not limit the study
population with sepsis, we have intentionally chosen
similar criteria to the only study underway on FES-CE in
ICU patients, which is primarily focused on muscle
structure and function [57].
Interventions
The flow of participants throughout the trial is shown in
Fig. 1 and the study procedures in Fig. 2. As soon as in-
formed consent has been obtained, and prior to
randomization, baseline testing including anthropomet-
ric examination will be performed. In addition, in pa-
tients with specific consent, a muscle biopsy will be
obtained and hyperinsulinaemic clamp will be performed
on the first morning (8.00–11.00 a.m.) and prior to the
start of enteral nutrition.
Standard care group
Both groups will receive usual best medical and nursing
care in the ICU, which includes daily sedation holds
when applicable and delirium 12-hourly monitoring (by
CAM-ICU scale [58]) and management as usual in the
routine practice. Respiratory physiotherapy will also be
delivered without alterations. The routine standard care
arm will undergo mobilization/rehabilitation delivered
by personnel not involved in the study in a usual, rou-
tine way. Details of physiotherapy treatment will be re-
corded but not protocolled in the standard care arm.
Intervention group
In the intervention arm, early goal-directed rehabilita-
tion is protocolled according to the patients’ condition
and degree of cooperation (Fig. 3), and there will be pre-
defined safety criteria, which are in accordance with
current recommendations for active rehabilitation of
critically ill ventilated adults [13]. Whilst the safety cri-
teria are binding for the study physiotherapist, the re-
habilitation protocol is not and the delivery of physical
exercise can be altered according to the actual patient’s
condition. However, any alteration and the reason for it
will be recorded. The intervention will start as soon as
possible and always within 72 h of ICU admission, con-
tinuing until ICU discharge. Supine cycling will be deliv-
ered as per protocol on a supine cycle ergometer
attached to a neuromuscular stimulator. Surface elec-
trodes will be applied to the gluteal, hamstring and
quadriceps muscles on both legs. The intensity of
muscle stimulation will be delivered at a level able to
cause visible contractions (confirmed by palpation if un-
certain) in all muscle groups without causing undue pain
or discomfort to the participant, according to a regime
specified by Parry et al. [44]. Once the patient is more
alert, and able to participate, they will be provided with
standardized encouragement to engage in therapy. To
increase the intervention workload, resistance will be in-
creased incrementally and cycling cadence. If a partici-
pant is readmitted to intensive care, the intervention will
be re-initiated. The intervention continues until day 28
or ICU discharge, whichever occurs earlier.
Methods
Enrolment and randomization
All patients admitted to participating ICUs are screened
daily by research nurses and all eligible patients or their
representatives are approached by investigators as soon as
possible, but always within 72 h of admission. Participants
for whom informed consent was obtained will be ran-
domly assigned (1:1) to receive either standard care or the
intervention using offsite independent randomization pro-
tocols (www.randomization.com) embedded in the elec-
tronic case report form. Randomization will be stratified
according to the presence or absence of sepsis and the
availability of a biopsy at baseline. There is no restriction
(blocking) during randomization.
Both the study team and clinical personnel will be
made aware of subject treatment allocation. The out-
come assessor is not involved in patient care and re-
mains blinded to treatment allocations.
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Fig. 1 Planned flowchart of patients enrolled into the trial. D7 day 7, D/C discharge, FES-CE functional electrical stimulation-assisted cycle
ergometry, ICU intensive care unit, tx treatment, NMS neuromuscular stimulation, PCBE passive cycling-based exercise
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Clinical data retrieval and handling
The ICUs are paperless and fully computerized, so vital
functions and other physiological parameters are moni-
tored and data are routinely stored in secure hospital
data bases via a protected dedicated network (MetaVi-
sion; IMD Soft Inc.). This includes data about nutritional
intake and urinary output. On top of this, research
nurses will input data into an electronic, secure, custom-
ized online case report form database (eCRF; accessible
at https://195.113.79.251:9090/apex/f?p=103:101:14992
036032980). Data protection and encryption is in ac-
cordance with the EU’s General Data Protection Regula-
tions as well as Czech data protection laws. The data
will be audited by on a regular basis, but at least after
each 10 patients are enrolled, by independent study
monitor. After the database is locked upon study com-
pletion, patients’ data will be de-identified and available
in full in a public database.
Urine samples will be collected daily, surfaced with
toluene and stored in a deep-freeze facility for later de-
termination of nitrogen content and 3-methyl histidine
levels (to calculate the muscle catabolism rate and nitro-
gen balance). In addition, all study patients will undergo
assessment by a study physiotherapist, which includes a
measurement of rectus muscle cross-sectional area on
both legs and, whenever the patient regains conscious-
ness, also muscle power by MRC score (standardized
testing of muscle power (0–5) for 12 muscle groups on
all four limbs, giving a score of 0–60 (60 suggesting nor-
mal muscle power)). Blood will be taken, and plasma
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. D day, D/C discharge, EGDR early goal-directed rehabilitation,
F-up follow-up, ICU intensive care unit, MRC Medical Research Council, MV mechanical ventilation, RHB rehabilitation, SF-36 Short Form 36, SOFA
Sequential Organ Failure Assessment, CCS Charlson comorbidity score, ROM range of motion, PFIT physical function test for use in the intensive care unit
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separated and frozen at − 80 °C for later analysis of cyto-
kines and hormone levels. This assessment will be re-
peated at day 7 intervals and at ICU discharge. At ICU
discharge, the patients and relatives will be asked to pro-
vide contact details for follow-up. After 6 months, the
patient or family will be contacted for structured inter-
view as required for the SF-36 questionnaire, and col-
lected using the RAND methodology (www.rand.org).
Whilst participants and the intervention physiotherapist
cannot be blinded to group allocation, research staff
assessing the outcome will be from a separate clinical
department (JG, BB, MH) and thus will remain blinded
to treatment allocation. Outcome assessors are familiar
with the SF-36, which is in routine use for other trials,
and received SF-36 re-training at induction to this trial.
Strategies to improve adherence to intervention mainly
include the 24/7 availability of one of the team of five re-
search nurses as well as one full-time physiotherapist
equivalent only reserved for study interventions, with
extra budgeting to cover physiotherapy sessions in the
intervention group during the weekend. The time of
physiotherapy sessions will be recorded by the physio-
therapist and randomly checked by a hidden independ-
ent assessor (bedside ICU nurse receiving specific
instructions). The primary outcome has been chosen
also with respect to the fact that it can be collected over
a structured telephone interview, thereby minimizing
missing data.
Complementary studies: insulin resistance and
mitochondrial function
These studies will be performed in addition to other
study procedures in a nested subgroup of patients, who
give specific consent. The first measurement will be per-
formed at baseline prior to randomization, ideally the
next morning after admission. Second measurement will
be performed on day 7 of ICU stay, i.e. after at least 5
days of intervention.
Muscle biopsy
Muscle biopsy will be performed from the vastus latera-
lis muscle using the Bergstrom needle biopsy technique.
Fig. 3 Protocol of intensified goal-directed rehabilitation. FES-CE functional electrical stimulation-assisted cycle ergometry, FIO2 fraction of inspired
oxygen, LL lower limb, RASS Richmond Agitation and Sedation Scale, UL upper limb
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The sample will be separated into three parts (50–100
mg each). One part will be immediately frozen in liquid
nitrogen for analysis of the protein/DNA ratio and for
protein expression studies. The second part will be fro-
zen in liquid nitrogen-cooled isopentone for muscle fibre
typing and immunohistochemistry analysis. The third
part put will be placed in BIOPS media on ice for the
preparation of homogenates and measurement of citrate
synthase activity, spectrophotometric analysis of the ac-
tivity of respiratory complexes I–IV [52] and western
blot analysis of respiratory complexes (as described in
[55]). In the fresh muscle homogenates, we will use
high-resolution respirometry (Oxygraph; Oroboros,
Austria) to determine the function of individual respira-
tory complexes in the cytosolic context and measure
basic functional metabolic indices by a method we have
recently developed and calibrated against isolated mito-
chondria [59]. We will specifically look at the degree of
mitochondrial uncoupling, the respiratory chain capacity
and the function of individual complexes, including
glycerol-3-phosphate shuttle. From the satellite cells we
will prepare a culture of myotubes, which will serve as
an in vitro model of skeletal muscle [60] and specifically
measure the in vitro ability of myotubes to oxidize fatty
acids by extracellular flux analysis (Seahorse Biosci-
ences). Frozen muscle samples will be stored at − 80 °C
for analysis of the DNA/protein ratio, mRNA and pro-
teins involved in the regulation of proteolysis, substrate
oxidation and anabolic pathways of skeletal muscle
(MuRF, FOXO, atrogins) as well as immunohistochemis-
try and typing of muscle fibres. In order to determine
which changes are caused by critical illness itself, we will
also obtain control samples (n = 15) from age, sex and
BMI-matched metabolically healthy volunteers undergo-
ing elective hip surgery at the Department of Ortho-
paedic Surgery. In addition, we will look at the change
of these indices after 7 days of critical illness and the in-
fluence of the intervention versus standard of care. We
will look at correlation of these parameters with muscle
power (i.e. compare the bioenergetics profile of skeletal
muscle in those who develop ICUAW and in those who
do not) and insulin resistance.
Insulin sensitivity and substrate oxidation will be mea-
sured after overnight fasting by hyperinsulinaemic eugly-
cemic clamp (as described in [61]). We will compare the




In studies of critical illness outcome at 6 months using
SF-36 scores, the standard deviation varied between 10
and 30 points. In order to have 80% power to detect a
15-point difference in SF-36 scores between control and
intervention at the level of significance p < 0.05 in the
population with a mean of 60 and SD of 30 [12], we
would need 108 subjects (54 in each arm). In order to
allow for deaths and dropouts, we plan to randomize
150 subjects.
Data analysis plan
The primary outcome and all secondary outcomes will
be compared between the intervention and standard of
care groups in an intention-to-treat population, with all
tests two-sided and with the level of significance set at
5%, after the primary outcome has been collected in the
last subject. There is no plan for any interim analysis.
We will perform exploratory analyses in pre-specified
subgroups of patients stratified according to APACHE
II, and the length of intervention. We will also perform
unadjusted analysis of odds ratio of being functionally
independent (defined as ability to walk, use a telephone,
self-care, use the toilet and groom) at 6 months after
ICU admission in patients in the intervention and stand-
ard of care groups. We will perform adjustments on the
disease severity (APACHE II score), admission diagnosis,
baseline functional status and age. Missing data for pri-
mary outcome will be dealt by reporting both worst-case
and per-protocol results; no imputation will be used.
Ethical considerations
This trial involves a two-tier consent process: first to the
rehabilitation intervention and then additionally to the
insulin clamp and muscle biopsies in a nested subgroup
within the primary trial. All patients meeting the afore-
mentioned criteria will be invited to participate and
asked to provide written informed consent. It is expected
that most screened patients will lack the capacity to pro-
vide informed consent. In this situation, the deferred
consent policy will be applied: patient’s next of kin
(NOK) will be approached, and be given verbal and writ-
ten information explaining the nature of the study given
information leaflet and asked to provide assent. Discus-
sion with the family will help inform the treating med-
ical team regarding a best interest decision for assent to
be recruited into the study. An option will be given to
participate in the trial, but not to undergo insulin clamps
and muscle biopsies. In a subgroup of patients when the
family is unavailable within the first 48 h, an independ-
ent physician will be asked to review inclusion and ex-
clusion criteria and weight benefits and risks of
participation in the trial – all patients enrolled based on
independent physician assent will proceed without insu-
lin clamps and muscle biopsies. Participants themselves
will be asked to provide ongoing consent as soon as they
regain capacity. Again, they will be offered the option to
continue participating in the trial without insulin clamps
and/or muscle biopsies, if they so wish. Details of all
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participants who refuse consent for muscle biopsy/insu-
lin clams will be recorded. All serious adverse events
that are suspected as being related to study interventions
will be reposted to the Research Ethics Board and regu-
latory authorities as per local legislation. Other adverse
events deemed to be related or possibly related to treat-
ment intervention will be discussed at regular monthly
meetings of the study team with the decision on further
action, as there is no formal steering committee for this
trial. The final decision-making and reporting responsi-
bility is with the principal investigator (FD). All adverse
events will be recorded in the eCRF. All protocol
amendments, should they be required, will be subjected
to a priori approval by the REB. Once implemented,
protocol amendments will be reported to the sponsor
and registration body (www.clinicaltrials.gov).
Replication of key aspects of trial methods and conduct
The trial is designed to be fully reproducible in an ICU
setting in larger, but not necessarily teaching or aca-
demic, hospitals, where the FES-CE equipment and
trained physiotherapists are available 7 days a week.
The sponsor of the study is a state-governed grant
agency that has not had nor will have any role in study
design; collection, management, analysis and interpret-
ation of data; writing of the report; or the decision to
submit the report for publication.
Dissemination of results
We will submit the main results of the trial in an open-
access peer-reviewed journal within 6months after the
150th subject has completed the 6-month follow-up
visit, which is expected to happen in Q2 of 2020. We
will make fully de-identified record-level raw data avail-
able in a public database Additional file 2.
Trial status
This trial is recruiting (recruitment began November
2016, expected finish November 2019) (first patient
recruited 4 October 2016, expected end of study 1 July
2020), protocol version 2.0 as of January 2018. For the full
WHO Trial Registration Data Set, see Additional file 1.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3745-1.
Additional file 1. WHO Trial Registration data set.
Additional file 2. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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